grant
Uncovering the mechanisms and implications of BST2 antagonism by SARS-CoV-2
Organization UNIVERSITY OF ROCHESTERLocation ROCHESTER, UNITED STATESPosted 1 Jul 2025Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY20252019 novel corona virus2019 novel coronavirus2019-nCoV2019-nCoV vaccineAPF-1ATP-Dependent Proteolysis Factor 1Ab-dependent cellular cytotoxicityAffinityAnti-viral AgentsAntibodiesAntibody-Dependent EnhancementAssayAutomobile DrivingAwardB.1.1.529BindingBioassayBiological AssayCOVID-19 antibodyCOVID-19 predispositionCOVID-19 susceptibilityCOVID-19 vaccineCOVID-19 virusCOVID-19 vulnerabilityCOVID19 virusCell BodyCell surfaceCellsClathrinCoV-2CoV2CollaborationsCommunicationCore FacilityCoronaviridaeCoronavirusCoronavirus disease 2019 predispositionCoronavirus disease 2019 susceptibilityCoronavirus disease 2019 vulnerabilityCytotoxic cellDNA mutationDefectDown-RegulationEducationEducational aspectsExternal DomainExtracellular DomainFc ReceptorFutureGenetic ChangeGenetic defectGenetic mutationGoalsHMG-20High Mobility Protein 20ImmuneImmune PrecipitationImmune responseImmunesImmunoprecipitationInternationalK lymphocyteKnowledgeLettersMacrophageMapsMeasuresMediatingMembraneMolecular InteractionMutationMφNK CellsNatural Killer CellsOmicron variantOrthocoronavirinaePredisposed to COVID-19Predisposed to SARS-CoV-2Predisposed to Severe acute respiratory syndrome coronavirus 2PredispositionPredisposition geneProcessProteinsPublicationsPublishingReportingResistanceRoleRouteSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV-2 B.1.1.529SARS-CoV-2 antibodySARS-CoV-2 omicronSARS-CoV-2 omicron variantSARS-CoV-2 predispositionSARS-CoV-2 susceptibilitySARS-CoV-2 vaccineSARS-CoV-2 vulnerabilitySARS-CoV2SARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-coronavirus-2 vaccineSARS-related corona virus 2SARS-related coronavirus 2SARSCoV2Scientific PublicationSevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome CoV 2 vaccineSevere Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2 predispositionSevere acute respiratory syndrome coronavirus 2 susceptibilitySevere acute respiratory syndrome coronavirus 2 vaccineSevere acute respiratory syndrome coronavirus 2 vulnerabilitySevere acute respiratory syndrome related corona virus 2Surface Plasmon ResonanceSusceptibilitySusceptibility GeneTestingTrainingTranslatingTravelUbiquitinUniversitiesVaccine DesignViralVirionVirusVirus ParticleVirus ReplicationWisconsinWorkWritingWuhan coronavirusantagonismantagonistanti-viral compoundanti-viral drugsanti-viral medicationanti-viral therapeuticanti-viralsantibody against COVID-19antibody against SARS-CoV-2antibody against coronavirus disease 2019antibody against severe acute respiratory syndrome coronavirus 2antibody dependent cell mediated cytotoxicityantibody dependent cytotoxicityantibody mediated cellular cytotoxicityantibody receptorantibody to COVID-19antibody to SARS-CoV-2antibody to coronavirus disease 2019antibody to severe acute respiratory syndrome coronavirus 2antibody-dependent cell cytotoxicityantibody-dependent cellular cytotoxicityantibody-dependent cellular phagocytosisantibody-mediated cytotoxicitybasebasesconferenceconventioncorona viruscoronavirus disease 2019 antibodycoronavirus disease 2019 vaccinecoronavirus disease 2019 viruscoronavirus disease-19 vaccinecoronavirus disease-19 virusdesigndesigningdrivingexperiencegenome mutationhCoV19host responseimmune system responseimmunoresponseimprovedmembrane structurenCoV vaccinenCoV-19 vaccinenCoV19 vaccinenCoV2omicron variant of COVID-19omicron variant of SARS-CoV-2predisposed to Coronavirus disease 2019predisposing genepressureresistantresponsesevere acute respiratory syndrome coronavirus 2 B.1.1.529severe acute respiratory syndrome coronavirus 2 antibodyskillssocial rolestructural biologysummitsusceptibility allelesusceptibility locussusceptibility variantsusceptible to COVID-19susceptible to Coronavirus disease 2019susceptible to SARS-CoV-2susceptible to Severe acute respiratory syndrome coronavirus 2symposiasymposiumvaccine against 2019-nCovvaccine against COVID-19vaccine against SARS-CoV-2vaccine against SARS-coronavirus-2vaccine against Severe Acute Respiratory Syndrome CoV 2vaccine against Severe acute respiratory syndrome coronavirus 2vaccine candidates against SARS-CoV-2vaccine efficacyvaccine for novel coronavirusvaccines preventing COVIDvaccines to prevent COVIDvariants of concernviral multiplicationviral replicationvirus multiplicationvulnerable to COVID-19vulnerable to Coronavirus disease 2019vulnerable to SARS-CoV-2vulnerable to Severe acute respiratory syndrome coronavirus 2
Description preview
PROJECT SUMMARY
BST2/Tetherin is a key factor of the cellular intrinsic immune response that broadly restricts enveloped viruses.
BST2 tethers nascent virions to the cell surface by embedding itself into cellular and viral membranes. Tethering
not only limits viral release, but also facilitates adaptive immune recognition of the infecting virus.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click